$34.09▴ 0.06%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+18.6%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Highdebt to assets
Weak
High leverage relative to its assets.
More coming: dilution / share-count creep.
Fair value
Overvalued
Trading about 21% above our fair-value range
Value-trap risk
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Sanara MedTech Inc.'s earnings-quality signal is not available yet. Revenue is growing strongly year over year. High leverage relative to its assets.
Key numbers
Recent news
Sentiment · last 30 days3 articles
0 bullish0 neutral3 bearish
Halper Sadeh LLC is Investigating Whether FBRX, LXFR, SMTI, MKTX are Obtaining Fair Deals for their Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: MarketAxess Holdings Inc. (Nasdaq – MKTX), CBIZ, Inc. (NYSE – CBZ), Sanara MedTech Inc. (Nasdaq – SMTI), TriCo Bancshares (Nasdaq – TCBK)
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.